Sandoz Sues FDA For Inaction On Omnitrope NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Lawsuit seeks a court declaration that the 505(b)(2) pathway “can be used for protein-based biologic drugs regulated under Section 505 of the FD&C Act.”
You may also be interested in...
Amphastar Seeks Court Order Requiring FDA To Approve Its Enoxaparin ANDA
Amphastar’s initial lawsuit against FDA achieved its stated goal: the agency released two shipments of raw heparin material the company is to use in producing generic Lovenox (enoxaparin).
Amphastar Seeks Court Order Requiring FDA To Approve Its Enoxaparin ANDA
Amphastar’s initial lawsuit against FDA achieved its stated goal: the agency released two shipments of raw heparin material the company is to use in producing generic Lovenox (enoxaparin).
FDA Must Take Action On Sandoz' Omnitrope Application, U.S. District Court says
The agency sees three options – appeal, approve or put to a hearing – following the decision which found that FDA had failed to meet its statutory timetable.